Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Boston Scientific Corporation (BSX) Q4 2025 Earnings Call Transcript
BSX beats Q4 EPS and revenue estimates and lifts margins, but shares slide 9.1% in pre-market as investors weigh outlook and guidance.
While the top- and bottom-line numbers for Boston Scientific (BSX) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Sales rose 16%, but the medical-device maker issued a soft forecast for the year, sending shares down premarket.
Boston Scientific (BSX) came out with quarterly earnings of $0.8 per share, beating the Zacks Consensus Estimate of $0.78 per share. This compares to earnings of $0.7 per share a year ago.
The medical-device maker beats quarterly earnings expectations but offers a disappointing outlook for the current quarter.
Beyond analysts' top-and-bottom-line estimates for Boston Scientific (BSX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2025.
BSX heads into Q4 earnings with strong MedSurg momentum and Cardiovascular growth, as revenue and EPS estimates point to double-digit gains.
In the closing of the recent trading day, Boston Scientific (BSX) stood at $92.51, denoting a +1.34% move from the preceding trading day.
Boston Scientific (BSX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Boston Scientific (BSX) shares have decreased by 8.5% over the past 5 trading days. This recent drop highlights revived worries regarding the initial earnings dilution stemming from its Penumbra acquisition, yet such significant declines often raise a challenging question: is this weakness transitory, or does it indicate more profound issues within the company?